News
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...
Barchart on MSN1h
This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst
Eli Lilly and Company (LLY), one of the world’s leading pharmaceutical giants, might have just unveiled its next major growth ...
Zacks Investment Research on MSN1h
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
Eli Lilly and Company LLY reported second-quarter 2025 adjusted earnings per share (“EPS”) of $6.31, which beat the Zacks ...
Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...
Seventeen of the complaints also name Lilly competitor Novo Nordisk Inc. as a defendant and make similar allegations about ...
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...
Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...
Medicines for diabetes show that Mounjaro outperforms Trulicity in reducing serious heart risks in diabetes patients ...
The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said ...
The trial enrolled more than 13,000 participants across 30 countries and lasted more than four and a half years. It was also the largest and longest study of tirzepatide --- the active ingredient in ...
In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback